ArticleMolecular therapy. Nucleic acids2021
PHF5A promotes colorectal cancerprogression by alternative splicing of TEAD2.
Article in Molecular therapy. Nucleic acids, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 42 citations in OpenAlex.
- Comprehensive analysis of the BID gene to uncover the role of novel alternative splicing isoforms in colon adenocarcinoma: a systematic review of literature and bioinformatics analysis.Cancer cell international · 2025Review
- Splicing control by PHF5A is crucial for melanoma cell survival.Cell proliferation · 2025Article
- Targeting RNA splicing modulation: new perspectives for anticancer strategy?Journal of experimental & clinical cancer research : CR · 2025Review
- Comprehensive analysis of PHF5A as a potential prognostic biomarker and therapeutic target across cancers and in hepatocellular carcinoma.BMC cancer · 2024Article
- SF3B3-regulated mTOR alternative splicing promotes colorectal cancer progression and metastasis.Journal of experimental & clinical cancer research : CR · 2024Article
- PHF5A promotes esophageal squamous cell carcinoma progression via stabilizing VEGFA.Biology direct · 2024Article
- PHF5A is a potential diagnostic, prognostic, and immunological biomarker in pan-cancer.Scientific reports · 2023Article
- KMT2A associates with PHF5A-PHF14-HMG20A-RAI1 subcomplex in pancreatic cancer stem cells and epigenetically regulates their characteristics.Nature communications · 2023Article
- PHF5A regulates the expression of the DOCK5 variant to promote HNSCC progression through p38 MAPK activation.Biology direct · 2023Article
- PHF5A as a new OncoTarget and therapeutic prospects.Heliyon · 2023Review
- Delineating the glioblastoma stemness by genes involved in cytoskeletal rearrangements and metabolic alterations.World journal of stem cells · 2023Review
- The phosphorylation of PHF5A by TrkA-ERK1/2-ABL1 cascade regulates centrosome separation.Cell death & disease · 2023Article
- [PHF5A Promotes Proliferation and Migration of Non-Small Cell Lung Cancer by Regulating of PI3K/AKT Pathway].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Article
- Research progress and therapeutic prospect of PHF5A acting as a new target for malignant tumors.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysregulated alternative splicing (AS) plays critical roles in driving cancer progression, and the underlying mechanisms remain largely unknown. Here, we demonstrated that PHF5A, a component of U2 small nuclear ribonucleoproteins, was frequently upregulated in colorectal cancer (CRC) samples and associated with poor prognosis. PHF5A promoted proliferation and metastasis of CRC cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.